What next for Alzheimer’s research after latest trial failure?

Loading player...
LONDON — Research on Alzheimer’s disease that afflicts an estimated 40m people worldwide has experienced a major setback when pharma company Biogen and its Japanese partner, Eisai announced that they are ending their phase three clinical trials for the drug aducanumab. They concluded that the drug had little chance of succeeding. It wiped almost a third off Biogen’s shares. The end of the trial was a blow for the theory by scientists that the symptoms of Alzheimer’s could be stopped if you manage to clear the build-up of amyloid plaques in ageing brains that destroy connections between nerve cells. And the conclusion at this point, has to be that we really do not know what is causing the disease and how to create an intervention with a pharmaceutical. The likely effect of the Biogen setback is that Big Pharma will retreat from research on Alzheimer’s disease for now, but hopefully this void will be filled by more government and public market funding. Trials are continuing at several universities who are looking at the possibility of using drugs already on the market for diabetes and inflammation, while there are other pharmaceutical companies looking at other approaches to tackle Alzheimer’s, but their research is at a very early stage. Bloomberg’s Carol Massar and Jason Kelly spoke to Senior Biotech Analyst, Asthika Goonewardene and Brian Skorney, Biotech and Pharma Analyst at Baird about the future of Biogen and whether it is time to abandon the amyloid plaque hypothesis. - Linda van Tilburg Learn more about your ad choices. Visit megaphone.fm/adchoices
27 Mar 2019 3AM English South Africa Investing · Business News

Other recent episodes

To study or to start a business? The choice that built Bubbadue

More than one in 10 university graduates in South Africa cannot find a job. With an economy that creates far too few jobs for the people entering it, and AI starting to eat into white-collar work, many school leavers and their parents are asking whether a degree is still the…
20 Nov 5AM 14 min

BN Edge | Michael Beaumont on ActionSA's coalition hand and the DA standoff

Michael Beaumont has been called the power behind ActionSA's throne, and he's the man running its coalition talks across Gauteng. Speaking to Alec Hogg hours before ActionSA's first sit-down with the DA, he said the DA had never once come to the table until then, and that his party had…
19 Nov 9AM 50 min